Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients
View Full Paper
Ask AI
Bookmark
Share
Key result
Apixaban, dabigatran, and rivaroxaban linked to up to ~39% lower stroke risk vs warfarin in AF.
- HR 0.61
- 95% CI 0.54-0.69
- n=285,292
Why the study?
The study was conducted to compare stroke/systemic embolism and major bleeding among patients with nonvalvular atrial fibrillation receiving NOACs or warfarin using multiple pooled data sources.
Do NOACs (apixaban, dabigatran, rivaroxaban) reduce stroke/systemic embolism and major bleeding compared to warfarin in patients with nonvalvular atrial fibrillation in real-world practice?
Population
285 292 nonvalvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin
Comparison
1:1 propensity score-matched NOAC-warfarin and NOAC-NOAC pairs across apixaban, dabigatran, rivaroxaban, and warfarin
Design
Retrospective observational pooled database study
Authors
Discussion
Loading...
Member takes
Implication
NOACs were associated with lower stroke risk in real-world nonvalvular AF; leaves open questions on bleeding safety and generalizability pending prospective trials.
Study Design
Type
Observational (n=285,292)
Multicenter
Yes
Structured PICO
Do NOACs (apixaban, dabigatran, rivaroxaban) reduce stroke/systemic embolism and major bleeding compared to warfarin in patients with nonvalvular atrial fibrillation in real-world practice?
P
Population
285,292 patients with nonvalvular atrial fibrillation (NVAF) pooled from US Medicare and 4 commercial claims databases, mean age ~71-74 years, ~54-59% male. Key inclusion: ≥1 pharmacy claim for apixaban, dabigatran, rivaroxaban, or warfarin between January 1, 2013, and September 30, 2015; continuous enrollment for ≥12 months. Key exclusion: prior OAC treatment within 12 months, valvular heart disease, venous thromboembolism, transient AF, heart valve replacement/transplant, pregnancy, or recent hip/knee replacement.
I
Intervention
Non-vitamin K antagonist oral anticoagulants (NOACs) including apixaban, dabigatran, or rivaroxaban (standard or lower doses based on index prescription).
C
Comparator
Warfarin (and head-to-head comparisons between NOACs), matched 1:1 using propensity scores based on demographics, Charlson Comorbidity Index, baseline bleeding/stroke history, comorbidities, and comedications.
O
Outcome
Time to first stroke/systemic embolism (including ischemic stroke, hemorrhagic stroke, and systemic embolism) and time to first major bleeding (including gastrointestinal bleeding, intracranial hemorrhage, and major bleeding at other key sites).hard clinical
Main Result
Effect estimate: HR 0.61 (95% CI 0.54-0.69)
In a large real-world cohort of patients with nonvalvular atrial fibrillation, NOACs were associated with lower rates of stroke/systemic embolism compared to warfarin, with varying safety profiles regarding major bleeding.
Limitations
- Retrospective observational design using healthcare claims data, subject to residual confounding.
- Outcome measures based on ICD-9-CM codes without clinical adjudication.
- Lack of laboratory values (e.g., INR) and clinical data (e.g., body weight, serum creatinine) to evaluate dose reduction criteria or time in therapeutic range.
- Inability to measure actual drug-taking behaviors.
- May not be generalizable to uninsured patients or those solely covered by other public health insurance plans.
- Inherent limitations of retrospective observational studies (e.g., potential unmeasured confounding)
Cite This Study
Lip et al. (2018) conducted an observational in Nonvalvular atrial fibrillation (n=285,292). Apixaban, dabigatran, or rivaroxaban vs. Warfarin was evaluated on Stroke/systemic embolism (SE) (Apixaban vs Warfarin) (HR 0.61, 95% CI 0.54-0.69). Apixaban (HR 0.61), dabigatran (HR 0.80), and rivaroxaban (HR 0.75) reduced the risk of stroke or systemic embolism compared to warfarin in patients with nonvalvular atrial fibrillation.
Topics
View Full Paper
Ask AI
Bookmark
Share